Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt falls 48.1% from a year ago

Net debt stood at $572.22M at the end of Q1 FY2026, down 48.1% from a year earlier and up 140.0% from the prior quarter. Over 3 fiscal years it compounded at -28.4% a year.

Context

  • Net debt amounted to 18.0% of total assets at the end of Q1 FY2026, down 13.8 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -48.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$572.22M+140.0% QoQ
Last fiscal yearDec 2025
$238.46M-0.7% YoY
Year agoMar 2025
$1.1B-48.1% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-48.1%——
1 year-0.7%——
3-year CAGR-28.4%——
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
238.46M USD
Year-over-year change
-0.7%

Net Debt vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's Mar 2026 net debt of $572.22M is the 2nd highest of the 11 companies compared; the peer median is -$180.68M.
  • Its year-over-year change of -48.1% is the 5th highest of 11, against a peer median of -64.2%.
  • Net debt amounts to 18.0% of total assets for SRPT, versus a peer median of 21.1%.
SRPT Competitors Peer median
Net Debt for SRPT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IONSIonis Pharmaceuticals, Inc.Sep 2026$1.86B +61.3%+27.1%63.7%
SRPTSarepta Therapeutics, Inc.Mar 2026$572.22M -48.1%-28.4%18.0%
DSGNDesign Therapeutics, Inc.Mar 2026-$10.04M +12.9%—4.4%
PEPGPepGen Inc.Mar 2026-$25.59M -0.9%—16.4%
NTLAIntellia Therapeutics, Inc.Mar 2026-$54.21M -610.7%—7.1%
CAPRCapricor Therapeutics, Inc.Mar 2026-$84.3M -248.8%—25.8%
SLDBSolid Biosciences Inc.Mar 2026-$277.07M -48.2%—65.5%
PTCTPTC Therapeutics, Inc.Jun 2026-$353.42M +43.8%+13.4%10.9%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026-$440.91M -340.4%—7.9%
WVEWave Life Sciences Ltd.Mar 2026-$528.88M -141.0%—90.6%
DYNDyne Therapeutics, Inc.Jun 2026-$656.24M -80.3%—66.0%
Peer median (excluding SRPT) -$180.68M-64.2%+20.2%21.1%

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.12B966.78M428.43M1.1B801.28M
Short-term Investments01.02B1.25B251.78M138.37M
Net Receivables172.75M261.6M436.98M649.73M519.61M
Inventory186.21M203.97M322.86M749.96M914.74M
Other Current Assets5.3M6.82M12.48M9.21M9.2M
Total Current Assets2.6B2.56B2.58B3.07B2.54B
Property, Plant & Equipment (Net)236.69M244.99M357.11M488.65M470.62M
Goodwill00000
Intangible Assets14.24M7.58M29.62M26.89M28.95M
Long-term Investments34.89M31.32M6.53M136.87M1.05M
Tax Assets00000
Other Non-current Assets258.06M286.62M291.99M237.3M311.15M
Total Non-current Assets543.88M570.51M685.25M889.71M811.77M
Total Assets3.15B3.13B3.26B3.96B3.35B
Account Payables76.74M95.88M164.92M214.44M280.84M
Short-term Debt00105.48M00
Tax Payables216K12.52M13.77M17.39M0
Deferred Revenue89.24M89.24M50.42M130.26M443.4M
Other Current Liabilities110.44M134.73M178.81M200.28M176.13M
Total Current Liabilities452.73M619.6M653.66M731.68M1.1B
Long-term Debt1.1B1.54B1.13B1.14B828.97M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)574.24M485M437M325M83.91M
Other Non-current Liabilities54.6M36.94M41.1M49.15M1.53M
Total Non-current Liabilities1.77B2.12B1.75B1.7B1.11B
Total Liabilities2.22B2.74B2.41B2.44B2.21B
Common Stock9K9K9K10K11K
Retained Earnings(3.21B)(3.91B)(4.45B)(4.21B)(4.88B)
Accumulated OCI(20K)(1.66M)918K(218K)272K
Other Stockholders Equity00000
Minority Interest00000
Total Equity928.01M384.95M859.34M1.53B1.14B
Total Debt1.15B1.62B1.4B1.34B1.04B
Net Debt(962.43M)650.58M968.38M240.06M238.46M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.